Cartwright’s current work is focused on examining the effects of state-level laws restricting access to abortion services on women’s lives in the United States. She has recently returned to reproductive health work in the U.S. context after 6 years of managing research and programs to inform policies that expand access to reproductive and maternal health pharmaceutical products globally.
Summarizes operations research in Zambia that trained health providers on the prophylactic distribution of misoprostol to women for prevention of postpartum hemorrhage at home births (approximately 52% of births).
Concludes that community health workers can provide injectable contraception with a comparable level of safety, effectiveness, and acceptability as clinic-based health providers in Northern Ethiopia.
Outlines a system-level framework for assessing the nationwide availability of the obstetric drug misoprostol in Tanzania, including indicators to gauge progress and recommendations for next steps toward ensuring full access for women.